$SCYX News

Guggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $33

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

UPDATE: SCYNEXIS Q2 Adj. EPS $(0.57) Misses $(0.51) Estimate, Sales $235.000K Beat $80.330K Estimate

SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Announces 1-For-8 Reverse Stock Split, Effective May 29

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Q1 EPS $(0.42) Misses $(0.12) Estimate

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS Announces Prospectus Of 87M Shares By Selling Stockholders

SCYNEXIS INC (NASDAQ:SCYX) Combines Minervini Trend Template with High-Growth Momentum Fundamentals

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics - Slideshow

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease

SCYNEXIS Announces $40.0 Million Private Placement

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS Announces $40M Private Placement, Warrants May Add $52M To Proceeds

SCYNEXIS Agrees With Poxel To Acquire PXL-770; $8M Upfront, Up To $188M Milestones